Evan Guillemin Biography and Net Worth

Director of Mesa Laboratories

Evan Guillemin is a principal of Select Equity Group LP and member of the firm’s management committee. He joined Select Equity in April 2004 as the firm’s chief financial officer and ran the operations and finance groups for several years. He is currently a senior analyst and associate portfolio manager for the firm. He serves as a director and chairman of the audit committee of Mesa Labs, sits on the board of Bremont Chronometers, a private watchmaker, and serves as a director of Shake Shack Enterprises, the parent company of the restaurant chain. Prior to joining Select Equity Group, he was chief financial officer, and then chief operating officer of Delia*s Inc., a publicly-traded retailing company. He also served as director of acquisitions at Primedia and an editor at International Thomson. Guillemin received a BA from Yale College and an MBA with distinction from Harvard Business School.

Guillemin joined Vera's Board of Trustees in 2014.

What is Evan Guillemin's net worth?: The estimated net worth of Evan Guillemin is at least $2.84 million as of August 18th, 2022. Mr. Guillemin owns 28,776 shares of Mesa Laboratories stock worth more than $2,837,026 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Guillemin may own. Learn More about Evan Guillemin's net worth.
How do I contact Evan Guillemin?: The corporate mailing address for Mr. Guillemin and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on Evan Guillemin's contact information.
Has Evan Guillemin been buying or selling shares of Mesa Laboratories?: Evan Guillemin has not been actively trading shares of Mesa Laboratories during the past quarter. Most recently, Evan Guillemin sold 3,692 shares of the business's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $196.12, for a transaction totalling $724,075.04. Following the completion of the sale, the director now directly owns 28,776 shares of the company's stock, valued at $5,643,549.12. Learn More on Evan Guillemin's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), and John Sullivan (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, insiders at the medical instruments supplier sold shares 3 times. They sold a total of 5,517 shares worth more than $642,010.16. The most recent insider tranaction occured on October, 28th when CEO Gary M Owens sold 2,518 shares worth more than $286,095.16. Insiders at Mesa Laboratories own 4.4% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 10/28/2024.

Evan Guillemin Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/18/2022	Sell	3,692	$196.12	$724,075.04	28,776
12/2/2021	Sell	2,320	$310.61	$720,615.20
7/16/2021	Sell	720	$282.18	$203,169.60	29,450
6/16/2021	Sell	720	$256.36	$184,579.20	30,170
5/17/2021	Sell	720	$244.25	$175,860.00	30,595
3/16/2021	Sell	720	$269.48	$194,025.60	32,035
11/13/2020	Sell	2,050	$274.30	$562,315.00	36,728
12/16/2019	Sell	7,500	$251.31	$1,884,825.00	40,848
2/20/2019	Sell	1,746	$232.31	$405,613.26	50,214
2/13/2019	Sell	3,254	$230.70	$750,697.80	51,468
12/10/2018	Sell	15,000	$212.72	$3,190,800.00	61,468
12/4/2018	Sell	2,000	$218.74	$437,480.00	61,468

Evan Guillemin Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $98.59

$97.90

$101.34

50 Day Range

MA: $122.05

$98.59

$135.91

2 Week Range

Now: $98.59

$83.68

$141.17

Volume

30,071 shs

Average Volume

40,266 shs

Market Capitalization

$535.34 million

P/E Ratio

N/A

Dividend Yield

0.64%

Beta

0.87

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.